FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308889668> ?p ?o ?g. }

• W4308889668 endingPage "251" @default.
• W4308889668 startingPage "241" @default.
• W4308889668 abstract "Autoimmune liver disease (AILD) comprises of autoimmune hepatitis (AIH), primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) with a spectrum of overlap amongst the three. We analyzed the spectrum and treatment outcomes of patients with AILD presenting to a tertiary care center in India.A retrospective analysis of AILD patients from June 2008 to April 2021 was performed. The diagnosis was based on clinical, biochemical, imaging, serological, and histological characteristics. Eligible patients received treatment depending on the disease stage. Biochemical response to treatment was defined as normalization of AST, ALT, bilirubin, and immunoglobulin G levels at 6 months in AIH, normalization of total bilirubin and/or albumin at 1 year in PBC and decrease in alkaline phosphatase (ALP) levels by 40% in PSC.Two hundred seventy-five patients were analyzed. AIH (58.54%) was most common, followed by an overlap of AIH-PBC (24%) and AIH-PSC (6.54%), PSC (6.18%), and PBC (4.72%). Most patients presented in 3rd or 4th decade, except PBC which occurred predominantly in 5th decade. The majority of patients were females (72.72%). Jaundice was the most common presentation seen in 60% of patients. Cirrhosis was present in 57.47% of patients. Patients with overlap had more pruritus (54.76 vs 6.83%), fatigue (63.1% vs 49.7%), hepatomegaly (52.4% vs 25.5%), and higher ALP (80.9% vs 37.7%) than patients with AIH alone. Acute presentation was seen in 33 patients (13.5%) with most having AIH flare. Five patients had acute liver failure (ALF) and 9 had acute-on-chronic liver failure (ACLF). ALF was associated with 80% mortality while 55.56% of patients with ACLF had a complete biochemical response to immunosuppression. Among patients with AIH and/or overlap who received immunosuppression, a complete biochemical response to immunosuppression was seen in 60.69% of patients. High ALT (OR 1.001 [1.000-1.003], P = 0.034), high albumin (OR 1.91 [1.05-3.48], P = 0.034) and low fibrosis on biopsy (OR 0.54 [0.33-0.91], P = 0.020) predicted complete response.AIH is the most common AILD followed by overlap syndromes, PSC and PBC in our cohort. Biochemical response to immunosuppression is seen in 60% of patients with AIH & low fibrosis score on histopathology predicts a complete response." @default.
• W4308889668 created "2022-11-18" @default.
• W4308889668 creator A5000393786 @default.
• W4308889668 creator A5017984515 @default.
• W4308889668 creator A5028481134 @default.
• W4308889668 creator A5037076474 @default.
• W4308889668 creator A5038267980 @default.
• W4308889668 creator A5040682018 @default.
• W4308889668 creator A5044538545 @default.
• W4308889668 creator A5045640684 @default.
• W4308889668 creator A5054713971 @default.
• W4308889668 creator A5057961402 @default.
• W4308889668 creator A5071567530 @default.
• W4308889668 creator A5072941129 @default.
• W4308889668 creator A5086116099 @default.
• W4308889668 date "2023-03-01" @default.
• W4308889668 modified "2023-10-01" @default.
• W4308889668 title "Spectrum of Autoimmune Liver Disease and Real-World Treatment Experience from a Tertiary Care Hospital" @default.
• W4308889668 cites W1964051982 @default.
• W4308889668 cites W1968221120 @default.
• W4308889668 cites W1973130325 @default.
• W4308889668 cites W1975876595 @default.
• W4308889668 cites W1984153101 @default.
• W4308889668 cites W1987523828 @default.
• W4308889668 cites W2005901103 @default.
• W4308889668 cites W2038745263 @default.
• W4308889668 cites W2050642916 @default.
• W4308889668 cites W2070335189 @default.
• W4308889668 cites W2075236087 @default.
• W4308889668 cites W2075774005 @default.
• W4308889668 cites W2111368337 @default.
• W4308889668 cites W2122417766 @default.
• W4308889668 cites W2146204659 @default.
• W4308889668 cites W2153174384 @default.
• W4308889668 cites W2413974049 @default.
• W4308889668 cites W2464809778 @default.
• W4308889668 cites W2466134523 @default.
• W4308889668 cites W2607461384 @default.
• W4308889668 cites W2745107259 @default.
• W4308889668 cites W2786456523 @default.
• W4308889668 cites W2886477432 @default.
• W4308889668 cites W2908045840 @default.
• W4308889668 cites W2943269142 @default.
• W4308889668 cites W2995815973 @default.
• W4308889668 cites W3174905293 @default.
• W4308889668 cites W3216859300 @default.
• W4308889668 cites W4211190027 @default.
• W4308889668 cites W4295008070 @default.
• W4308889668 doi "https://doi.org/10.1016/j.jceh.2022.11.002" @default.
• W4308889668 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36950480" @default.
• W4308889668 hasPublicationYear "2023" @default.
• W4308889668 type Work @default.
• W4308889668 citedByCount "2" @default.
• W4308889668 countsByYear W43088896682023 @default.
• W4308889668 crossrefType "journal-article" @default.
• W4308889668 hasAuthorship W4308889668A5000393786 @default.
• W4308889668 hasAuthorship W4308889668A5017984515 @default.
• W4308889668 hasAuthorship W4308889668A5028481134 @default.
• W4308889668 hasAuthorship W4308889668A5037076474 @default.
• W4308889668 hasAuthorship W4308889668A5038267980 @default.
• W4308889668 hasAuthorship W4308889668A5040682018 @default.
• W4308889668 hasAuthorship W4308889668A5044538545 @default.
• W4308889668 hasAuthorship W4308889668A5045640684 @default.
• W4308889668 hasAuthorship W4308889668A5054713971 @default.
• W4308889668 hasAuthorship W4308889668A5057961402 @default.
• W4308889668 hasAuthorship W4308889668A5071567530 @default.
• W4308889668 hasAuthorship W4308889668A5072941129 @default.
• W4308889668 hasAuthorship W4308889668A5086116099 @default.
• W4308889668 hasBestOaLocation W43088896681 @default.
• W4308889668 hasConcept C126322002 @default.
• W4308889668 hasConcept C159654299 @default.
• W4308889668 hasConcept C203014093 @default.
• W4308889668 hasConcept C2775941666 @default.
• W4308889668 hasConcept C2777075537 @default.
• W4308889668 hasConcept C2777203481 @default.
• W4308889668 hasConcept C2777513400 @default.
• W4308889668 hasConcept C2778456037 @default.
• W4308889668 hasConcept C2779134260 @default.
• W4308889668 hasConcept C2780366471 @default.
• W4308889668 hasConcept C2780615123 @default.
• W4308889668 hasConcept C45189115 @default.
• W4308889668 hasConcept C71924100 @default.
• W4308889668 hasConcept C90924648 @default.
• W4308889668 hasConceptScore W4308889668C126322002 @default.
• W4308889668 hasConceptScore W4308889668C159654299 @default.
• W4308889668 hasConceptScore W4308889668C203014093 @default.
• W4308889668 hasConceptScore W4308889668C2775941666 @default.
• W4308889668 hasConceptScore W4308889668C2777075537 @default.
• W4308889668 hasConceptScore W4308889668C2777203481 @default.
• W4308889668 hasConceptScore W4308889668C2777513400 @default.
• W4308889668 hasConceptScore W4308889668C2778456037 @default.
• W4308889668 hasConceptScore W4308889668C2779134260 @default.
• W4308889668 hasConceptScore W4308889668C2780366471 @default.
• W4308889668 hasConceptScore W4308889668C2780615123 @default.
• W4308889668 hasConceptScore W4308889668C45189115 @default.
• W4308889668 hasConceptScore W4308889668C71924100 @default.
• W4308889668 hasConceptScore W4308889668C90924648 @default.
• W4308889668 hasIssue "2" @default.

• next